logo-loader
viewAlgernon Pharmaceuticals Inc.

Full interview: Algernon Announces Regulatory Submission for COVID trial in South Korea

Algernon (CSE:AGN-OTCQB: AGNPF) CEO Christopher Moreau joined Steve Darling from Proactive Vancouver to discuss another development for their repurposed drug Ifenprodil. Moreau giving Proactive more details about the study which will consist of 40 patients and will deal with those currently sick with the coronavirus.

Quick facts: Algernon Pharmaceuticals Inc.

Price: 0.325 CAD

CSE:AGN
Market: CSE
Market Cap: $29.27 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Fax Capital CEO talks investment and aligning with the right...

Fax Capital (TSE: FXC-) CEO Blair Driscoll joined Steve Darling from Proactive Vancouver to discuss the investment holding company that intends to invest in approximately 10 to 15 high-quality small-cap public and private businesses located primarily in Canada. Driscoll tells Proactive why...

4 hours, 9 minutes ago

2 min read